We demonstrated that adjuvant pharmacological suppression of circulating hPRL or inhibition of hPRLR significantly inhibited growth of established latent metastatic lung lesions of a therapy-naïve ER+ breast cancer PDX model. The gene discussed is PRLR; the disease is breast carcinoma.